Deng Jie, Li Jiayuan, Xu Lian, Yi Tianjin
Department of Obstetrics and Gynecology, Key Laboratory of Birth Defects and Related Diseases of Women and Children of Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
The Third People's Hospital of Xindu District, Chengdu, 610041, People's Republic of China.
Arch Gynecol Obstet. 2025 Apr 24. doi: 10.1007/s00404-025-08025-3.
To evaluate the clinicopathologic characteristics and survival outcomes of ovarian clear cell carcinoma (OCCC) patients with different endometriosis statuses.
This retrospective study included OCCC patients diagnosed between 2012 and 2021, classified into three groups based on the Sampson and Scott criteria: Without (no endometriosis), Arising (OCCC arising from endometriosis), and Coexisting (OCCC coexisting with endometriosis). Clinical and pathological characteristics were compared across groups, and survival outcomes were analyzed using Kaplan-Meier methods. Prognostic factors for progression-free survival (PFS) and overall survival (OS) were identified through univariate and multivariate analyses.
Among 242 patients, 53.7% were in the Without group, 29.3% in the Arising group, and 16.9% in the Coexisting group. The Arising group had the highest prevalence of early FIGO stage disease (91.6%) compared to the Coexisting (75.6%, p = 0.041) and Without (67.7%, p = 0.000) groups. Lymph-node metastasis was significantly lower in the Arising group (2.8%) than in the Coexisting (19.5%, p = 0.010) and Without (10%, p = 0.011) groups. Notably, the Arising group demonstrated unique atypical endometriosis features. In univariate analysis, the presence of endometriosis (either arising from or coexisting with endometriosis) was associated with improved PFS (p = 0.004 and p = 0.009, respectively); however, multivariate analysis confirms only coexisting with endometriosis as an independent factor (HR: 0.11, 95% CI: 0.01-0.84). For OS, the Arising group demonstrated the most significant benefit, with a 5-year OS of 92.4% compared to the Coexisting group (83.9%, p = 0.293) and the Without group (62.6%, p = 0.023). Multivariate analysis identified only FIGO stage (HR: 5.89, 95% CI: 2.06-16.82) as an independent prognostic factor for OS, while endometriosis did not reach statistical significance (HR: 0.62, 95% CI: 0.26-1.53).
Classifying OCCC with endometriosis statuses reveals distinct prognostic patterns. Coexisting with endometriosis positively impacts PFS, while the Arising subgroup shows the most significant OS benefit but may be confounded with other factors.
评估不同子宫内膜异位症状态的卵巢透明细胞癌(OCCC)患者的临床病理特征和生存结局。
这项回顾性研究纳入了2012年至2021年期间诊断的OCCC患者,根据桑普森和斯科特标准分为三组:无(无子宫内膜异位症)、起源(起源于子宫内膜异位症的OCCC)和并存(与子宫内膜异位症并存的OCCC)。比较各组的临床和病理特征,并使用Kaplan-Meier方法分析生存结局。通过单因素和多因素分析确定无进展生存期(PFS)和总生存期(OS)的预后因素。
在242例患者中,53.7%属于无组,29.3%属于起源组,16.9%属于并存组。与并存组(75.6%,p = 0.041)和无组(67.7%,p = 0.000)相比,起源组早期FIGO分期疾病的患病率最高(91.6%)。起源组的淋巴结转移率(2.8%)显著低于并存组(19.5%,p = 0.010)和无组(10%,p = 0.011)。值得注意的是起源组表现出独特的非典型子宫内膜异位症特征。在单因素分析中,子宫内膜异位症的存在(起源于或与子宫内膜异位症并存)与PFS改善相关(分别为p = 0.004和p = 0.009);然而,多因素分析仅确认与子宫内膜异位症并存是一个独立因素(HR:0.11,95%CI:0.01 - 0.84)。对于OS,起源组显示出最显著的获益,5年OS为92.4%,相比之下并存组为83.9%(p = 0.293),无组为62.6%(p = 0.023)。多因素分析仅确定FIGO分期(HR:5.89,95%CI:2.06 - 16.82)是OS的独立预后因素,而子宫内膜异位症未达到统计学意义(HR:0.62,95%CI:0.26 - 1.53)。
根据子宫内膜异位症状态对OCCC进行分类揭示了不同的预后模式。与子宫内膜异位症并存对PFS有积极影响,而起源亚组显示出最显著的OS获益,但可能与其他因素混淆。